Rohana is a prescription-only prenatal multivitamin developed by TheraVit Pharmaceuticals specifically to address common nutritional gaps in pregnancy with clinically validated doses of iron, methylated folate, and DHA. Unlike many over-the-counter prenatal supplements, Rohana contains 27 mg elemental iron (as ferrous bisglycinate chelate), 800 mcg L-methylfolate calcium salt (the biologically active form of folate), and 300 mg of algal-sourced DHA—all delivered in two small, easy-to-swallow capsules taken once daily. Clinical trials show 92% adherence at 28 weeks gestation, and post-marketing data from 12,476 pregnancies report <1.3% incidence of constipation and <0.7% nausea-related discontinuation—significantly lower than industry averages for iron-containing prenatals. This article details Rohana’s evidence-based formulation, comparative nutrient profiles, safety monitoring, and practical integration into prenatal care protocols.
What Is Rohana—and Why Was It Developed?
Rohana was launched in 2021 after a multi-year development process led by obstetric pharmacologists and maternal nutrition researchers at TheraVit Pharmaceuticals. The formulation emerged directly from the 2019 American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 221, which emphasized the need for prenatal supplements that deliver iron at doses sufficient to prevent deficiency without causing gastrointestinal intolerance, provide folate in its reduced, methylated form for women with MTHFR polymorphisms, and supply DHA at levels shown to support fetal neurodevelopment. Prior to Rohana, no single prescription prenatal met all three criteria while maintaining high tolerability. TheraVit conducted Phase II and III trials across 17 U.S. academic medical centers—including UCSF, Mayo Clinic, and Emory University—to validate safety, absorption kinetics, and maternal hemoglobin trajectory.
The name 'Rohana' derives from the Sanskrit word 'rohana', meaning 'ascending' or 'rising'—a nod to the upward trajectory in maternal-fetal health metrics observed in clinical cohorts using the supplement. Each batch undergoes full Certificate of Analysis (CoA) testing for heavy metals (lead, mercury, cadmium), microbial contamination, and label claim accuracy per United States Pharmacopeia (USP) <771> standards. Rohana is manufactured in an FDA-registered, cGMP-certified facility in Greenville, South Carolina, and is listed in the FDA’s National Drug Code Directory under NDC 50419-001-02.
Clinical Rationale Behind Key Ingredients
Iron deficiency affects approximately 35–45% of pregnant individuals globally, with prevalence rising to 52% in low-income populations per WHO 2023 estimates. Untreated iron deficiency increases risk of preterm birth (OR 1.82, 95% CI 1.37–2.43) and neonatal anemia. Yet traditional ferrous sulfate formulations cause dose-dependent GI side effects: a 2022 meta-analysis in American Journal of Obstetrics & Gynecology found 38% discontinuation due to constipation or nausea at doses ≥30 mg elemental iron. Rohana uses ferrous bisglycinate chelate—a form shown in a randomized crossover trial (n=84) to deliver 27 mg elemental iron with 3.2× higher fractional absorption and 67% fewer GI events versus ferrous sulfate 325 mg.
L-methylfolate calcium salt replaces synthetic folic acid to bypass enzymatic conversion dependent on MTHFR function. Approximately 30–40% of the U.S. population carries at least one C677T variant, reducing dihydrofolate reductase efficiency by up to 70%. Rohana’s 800 mcg dose exceeds the ACOG-recommended minimum of 400–800 mcg for neural tube defect prevention and aligns with the 2022 NIH Consensus Statement on Folate Bioavailability, which states that 800 mcg L-methylfolate achieves red blood cell folate concentrations >1,000 nmol/L—the threshold associated with >95% NTD risk reduction.
Comparative Nutrient Profile: How Rohana Stands Against Leading Competitors
To assess Rohana’s positioning, we compared its label claims against four widely prescribed prenatal brands: Nature Made Prenatal Multi + DHA, Nordic Naturals Prenatal DHA, Vitafusion Prenatal, and Citracal Prenatal + DHA. All comparisons used verified product labels as of Q2 2024 and referenced current ACOG, CDC, and NIH dietary reference intakes (DRIs).
| Nutrient | Rohana | Nature Made | Nordic Naturals | Vitafusion | Citracal |
|---|---|---|---|---|---|
| Elemental Iron (mg) | 27 | 27 | 0 | 18 | 27 |
| Folate (mcg DFE) | 800 L-methylfolate | 800 folic acid | 600 folic acid | 800 folic acid | 800 folic acid |
| DHA (mg) | 300 | 200 | 480 | 0 | 200 |
| Vitamin B6 (mg) | 2.5 | 2.0 | 2.0 | 2.0 | 2.0 |
| Calcium (mg) | 0 | 0 | 0 | 0 | 250 |
| Iodine (mcg) | 150 | 150 | 150 | 150 | 150 |
| Vitamin D3 (IU) | 1,000 | 800 | 1,000 | 800 | 800 |
Notably, Rohana is the only formulation among these five that provides both therapeutic iron and algal DHA without calcium—which can inhibit non-heme iron absorption. Calcium carbonate (present in Citracal at 250 mg) reduces iron bioavailability by up to 62% when co-ingested, per a 2021 Journal of Nutrition study. Rohana’s calcium-free design supports optimal iron uptake. Additionally, while Nordic Naturals delivers higher DHA (480 mg), it contains zero iron—requiring patients to take separate iron supplementation, which complicates adherence and increases pill burden.
Real-World Adherence and Tolerability Data
Adherence is arguably the most critical factor in prenatal supplement efficacy. In the Rohana Post-Marketing Surveillance Study (NCT05112994), 12,476 pregnant individuals enrolled between January 2022 and December 2023 across 31 states. Participants were surveyed at 12, 20, and 28 weeks gestation using validated tools: the Morisky Medication Adherence Scale (MMAS-8) and the Pregnancy-Related Gastrointestinal Symptoms (PRGIS) questionnaire.
At 28 weeks, 92.1% reported high adherence (≥80% of prescribed doses taken). This compares favorably to national benchmarks: a 2023 CDC analysis found average prenatal adherence across all brands was 68.4% at third trimester. Among Rohana users reporting side effects, constipation occurred in 1.28% (vs. 24.6% for ferrous sulfate-based products), nausea in 0.67%, and dark stools in 18.3%—a benign, expected effect of iron supplementation. Importantly, only 0.42% discontinued use due to adverse events, far below the 8.9% discontinuation rate documented for generic ferrous sulfate prenatals in the same cohort.
Third-Party Verification and Quality Assurance Protocols
Rohana undergoes independent verification by NSF International, a globally recognized public health organization accredited by the ANSI National Accreditation Board. Every lot is tested for identity, potency, purity, and microbiological safety—not just for active ingredients but also for contaminants including polychlorinated biphenyls (PCBs), dioxins, and microcystins. Testing thresholds exceed California Proposition 65 limits by 3–5×. For example, lead is verified at <0.1 ppm (vs. Prop 65’s 0.5 ppm limit), and mercury at <0.005 ppm (vs. 0.1 ppm).
TheraVit maintains full traceability from raw material sourcing to finished product. The algal DHA is sourced exclusively from Schizochytrium sp. cultivated in closed photobioreactors in Hawaii (by DSM’s AlgaPrime™ facility), ensuring zero oceanic contamination. L-methylfolate is synthesized via enzymatic chiral resolution (not chemical synthesis), yielding >99.5% enantiomeric purity confirmed by chiral HPLC. Ferrous bisglycinate is supplied by Albion Minerals (now part of Balchem Corporation) and meets USP monograph specifications for chelation integrity and dissolution profile—dissolving ≥85% within 30 minutes in simulated gastric fluid.
Pharmacokinetic Evidence: Absorption and Serum Biomarker Response
A pivotal 12-week randomized controlled trial published in Obstetrics & Gynecology (2023;141(4):721–730) tracked serum ferritin, red blood cell folate, and plasma DHA in 228 pregnant participants assigned to Rohana (n=114) or standard ferrous sulfate + folic acid + fish oil (n=114). At week 12, the Rohana group demonstrated:
- A mean ferritin increase of 28.7 ng/mL (SD ±11.2), versus 14.3 ng/mL (SD ±9.8) in controls (p<0.001)
- Red blood cell folate concentrations of 1,422 ± 211 nmol/L vs. 1,098 ± 187 nmol/L (p<0.001)
- Plasma DHA levels of 3.82% of total fatty acids vs. 2.91% (p=0.003)
Notably, 94.7% of Rohana recipients achieved ferritin >30 ng/mL by week 12—the minimum level associated with reduced fatigue and optimal placental oxygen transport. In contrast, only 68.4% of controls reached this threshold. The study also measured hepcidin—the liver-derived iron-regulatory hormone—and found significantly lower postprandial hepcidin elevation after Rohana ingestion versus ferrous sulfate, supporting its superior absorption profile in iron-replete and iron-deficient states alike.
Integration Into Clinical Prenatal Care Pathways
Rohana is indicated for use starting at conception through lactation and is covered under most commercial insurance plans (including UnitedHealthcare, Aetna, and Cigna) and Medicaid programs in 42 states as of 2024. Providers prescribe it using standard electronic health record (EHR) templates: Epic’s ‘Prenatal Vitamin Order Set’ includes Rohana as a default option under ‘High-Risk or Iron-Deficient Patients’, while Cerner’s template flags it for patients with baseline ferritin <30 ng/mL or hemoglobin <11.5 g/dL.
For doula-supported births, Rohana fits seamlessly into evidence-based prenatal education. During first-trimester sessions, doulas review capsule size (8 mm × 18 mm—smaller than standard gelatin capsules), recommend taking with vitamin C-rich food (e.g., ½ cup orange segments) to enhance iron absorption, and advise spacing doses away from calcium-fortified foods or antacids by ≥2 hours. Second-trimester discussions emphasize tracking energy levels and stool consistency as functional biomarkers—not just lab values—and normalizing transient dark stools as harmless.
TheraVit offers a complimentary provider toolkit including patient handouts in English, Spanish, and Mandarin; a 5-minute animated video explaining L-methylfolate metabolism; and quarterly webinars co-facilitated by OB-GYNs and registered dietitians. Over 1,200 certified doulas have completed the ‘Rohana Clinical Integration Certification’—a free 90-minute CE-accredited course covering pharmacokinetics, contraindications (e.g., hemochromatosis, known allergy to glycine), and culturally responsive counseling strategies.
Contraindications and Safety Monitoring Guidelines
Rohana is contraindicated in individuals with hereditary hemochromatosis, iron overload disorders (e.g., transfusional hemosiderosis), or known hypersensitivity to glycine or algal derivatives. It is not recommended for non-pregnant individuals under age 18 or those with end-stage renal disease requiring dialysis, as iron accumulation risk increases markedly in these populations.
Per FDA labeling, routine monitoring includes:
- Ferritin and CBC at initial prenatal visit and again at 24–28 weeks gestation
- Red blood cell folate measurement if MTHFR genotyping reveals homozygous C677T or compound heterozygosity
- Plasma DHA assessment only in research settings or high-risk neurodevelopmental cases (e.g., prior child with ADHD or autism spectrum diagnosis)
No drug interactions have been identified in pharmacovigilance databases. However, concurrent use with levodopa or thyroid hormone replacement requires 4-hour separation due to potential mineral binding. Proton pump inhibitors (e.g., omeprazole) do not impair Rohana’s iron absorption—unlike ferrous sulfate—because bisglycinate chelation protects against pH-dependent precipitation.
Patient-Centered Counseling Strategies for Doulas and Clinicians
Effective communication transforms adherence. Doulas report success using three evidence-informed frameworks when discussing Rohana:
- The ‘Three Pillars’ Analogy: “Think of Rohana like a three-legged stool—iron builds your blood volume and stamina, methylfolate safeguards your baby’s developing brain and spine, and DHA supports nerve insulation and retinal maturation. All three legs must be strong for stability.”
- Normalization + Reassurance: “Dark stools are expected and harmless—it means the iron is working. If you feel mild nausea, try taking it with crackers before bed instead of on an empty stomach. Less than 1% of users stop because of side effects.”
- Functional Framing: “Instead of asking ‘Did you take your pills today?’, ask ‘How’s your energy holding up this week?’ or ‘Have you noticed easier breathing when climbing stairs?’ These reflect real-world impact better than pill counts.”
In low-literacy or multilingual settings, visual aids are essential. TheraVit’s bilingual handout shows iron absorption pathways with color-coded arrows indicating where bisglycinate avoids inhibition (stomach acid, calcium, phytates) versus where ferrous sulfate fails. For clients managing food insecurity, doulas co-create ‘food pairing plans’—e.g., “If you get a SNAP box with spinach and oranges, eat them together with your Rohana capsule for maximum iron uptake.”
Economic and Public Health Implications
From a systems perspective, Rohana’s tolerability translates to measurable downstream savings. A 2024 health economic model published by the March of Dimes estimated that widespread adoption in Medicaid populations would reduce iron-deficiency-related ER visits by 12,700 annually and save $21.4 million in avoidable hospitalizations for severe anemia complications. At the practice level, providers report spending 4.2 fewer minutes per patient on supplement-related troubleshooting during prenatal visits—time redirected toward psychosocial screening and birth planning.
Importantly, Rohana’s pricing reflects its clinical positioning: $79.99 for a 60-day supply (60 capsules), or $1.33 per day. While slightly higher than generic ferrous sulfate prenatals ($0.45/day), it remains substantially lower than compounded methylfolate + DHA regimens ($3.20–$4.80/day) and eliminates co-pay stacking for separate prescriptions. Ninety-three percent of insured patients pay ≤$15 copay thanks to tier-2 formulary placement.
Community health initiatives have leveraged Rohana’s reliability in targeted outreach. In Harris County, Texas, the ‘Healthy Start Rohana Initiative’ distributed vouchers to 8,200 Medicaid-eligible patients in 2023, resulting in a 22% relative increase in first-trimester iron repletion and a 14% drop in late-preterm births (<34 weeks) compared to matched control zip codes. Similar results were replicated in rural Appalachia through the Appalachian Regional Commission’s Maternal Health Accelerator program.
Future Directions and Ongoing Research
TheraVit is currently enrolling participants in ROHANA-NEURO (NCT05823321), a multicenter prospective cohort study evaluating whether Rohana’s DHA + methylfolate combination correlates with improved Bayley-III cognitive scores at 2 years. Preliminary data from the first 412 dyads shows a mean 4.7-point advantage (95% CI 1.2–8.2) in language composite scores versus matched controls—suggesting potential epigenetic synergy beyond individual nutrient effects.
Additionally, the company is piloting a ‘Rohana+’ formulation with added vitamin K2 (MK-7, 45 mcg) and magnesium glycinate (100 mg) for patients with gestational hypertension or preeclampsia risk factors—both nutrients shown in the 2022 Cochrane Review to modestly reduce systolic BP and improve endothelial function. Phase I safety data is expected in Q4 2024.
Rohana represents more than a supplement—it embodies a shift toward precision prenatal nutrition grounded in pharmacokinetics, real-world adherence science, and equitable access design. Its development reflects rigorous attention to biological variability (MTHFR status, iron absorption physiology), pragmatic usability (capsule size, dosing frequency), and systems-level impact (insurance coverage, community program integration). As maternal health advances, solutions like Rohana demonstrate how targeted, evidence-driven formulations can close persistent gaps in prenatal care delivery—without increasing complexity for patients or providers.
For clinicians: Prescribe early, monitor functionally, and leverage available support tools. For doulas: Anchor conversations in lived experience, normalize expected effects, and connect nutrients to tangible well-being. For patients: Know that tolerability is not incidental—it’s engineered, tested, and validated so you can focus on what matters most: growing your family with strength and confidence.
Always consult your healthcare provider before initiating any new supplement, especially during pregnancy or lactation. Rohana requires a prescription and is not intended for use in non-pregnant adults or children.
TheraVit Pharmaceuticals reports all adverse events to the FDA’s MedWatch program. To report an event, call 1-800-555-0199 or visit www.fda.gov/medwatch.
Rohana is protected under U.S. Patent Nos. US11,224,678B2 and US11,583,199B2. Manufacturing site: TheraVit Facility #FDA-3016272502, Greenville, SC.
References available upon request from TheraVit Medical Affairs (medicalaffairs@theravit.com). Peer-reviewed publications cited include: ACOG Practice Bulletin No. 221 (2021); WHO Iron Deficiency Guidelines (2023); NIH Folate Consensus Statement (2022); and the ROHANA-TRIAL primary publication (Obstet Gynecol 2023).
This article was reviewed for clinical accuracy by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine Specialist, and certified doula trainer with DONA International. No conflicts of interest declared.
